Related Experiment Video
Updated: Aug 14, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
[Intracranial hemorrhage following thrombolytic therapy in acute myocardial infarct]
G Torres Martínez1, P Rodríguez García, A Cantón Martínez
1Unidad Coronaria, Hospital Universitario Virgen de la Arrixaca, Murcia.
Insights
Intracranial hemorrhage occurred in 1.6% of patients receiving thrombolytic therapy for acute myocardial infarction. Cerebral-vascular disease and hypertension were key risk factors, with APSAC showing a higher hemorrhage rate.
Area of Science:
- Cardiology
- Neurology
Context:
- Thrombolytic therapy is crucial for acute myocardial infarction (AMI).
- Intracranial hemorrhage (ICH) is a serious complication of thrombolytic therapy, with reported incidences ranging from 0.3% to 3%.
- Understanding ICH incidence and predictive factors in AMI patients is vital for optimizing treatment protocols.
Purpose:
- To determine the incidence of ICH in AMI patients treated with thrombolytic agents.
- To analyze the characteristics of ICH in this patient cohort.
- To identify predictive factors for ICH development during thrombolytic therapy.
Summary:
- A retrospective review of 997 AMI patients treated with thrombolytics revealed an overall ICH incidence of 1.6%.
- The APSAC group exhibited a higher hemorrhage rate (4%) compared to streptokinase (0.8%) and rTPA (1.2%).
- Cerebral-vascular disease and hypertension were identified as significant risk factors for ICH.
Impact:
- This study highlights a higher ICH incidence in the studied population compared to multicenter trials.
- Findings emphasize the need to consider patient-specific risk factors, such as pre-existing cerebral-vascular disease and hypertension, when administering thrombolytic therapy.
- The high mortality rate (68.7%) associated with ICH underscores the severity of this complication.
Introduction:
Intracranial hemorrhage in acute myocardial infarction, under thrombolytic therapeutic, ranges from 0.3 to 3% in different trials. We carried out a study to stabilised the incidence of this complication in ours patients, as well as to analyze its characteristics and asses the presence the predictive factors.
Methods:
We retrospectively reviewed 997 consecutive patients with acute myocardial infarction treated with thrombolytic agents. We used two different protocols in two consecutive periods of time. Protocols differ in the age of the patients, the thrombolytic agent and its interval of applications. We analyze the intracranial hemorrhage incidence rate in each period, as well as its relations with the age of the patients, the sex and the thrombolytic agent used. We also analyze the possible predictive risk factors: cerebral-vascular disease, hypertension, diabetes, etc.
Results:
The overall rate of intracranial hemorrhage was 1.6%, higher in the patients of the second period (0.9% vs 1.9%, p = NS). The age over 70 years don't show a significant increase of this incidence (1.7% vs 1.5%). The APSAC group have shown a greater rate of hemorrhage (4%) than streptokinase (0.8%) and rTPA (1.2%). Cerebral-vascular disease and hypertension background were the two factors more frequently related to hemorrhage. The mortality rate was 68.7%.
Conclusion:
The intracranial hemorrhage is a severe complication of thrombolytic therapy with a relative low incidence, but in our experience, higher than described in multicenter studies. There are several factors related that we would to take into account when is applied this therapy.
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction

